Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

274.57 +1.84 (+0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 548,759
Open 271.84
Bid (Size) 267.09 (1)
Ask (Size) 277.83 (1)
Prev. Close 272.73
Today's Range 270.83 - 278.24
52wk Range 141.97 - 287.55
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Via Benzinga
Alnylam to Webcast TTR Investor Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+40.86%
+40.86%
1 Month
+2.02%
+2.02%
3 Month
+11.99%
+11.99%
6 Month
+77.84%
+77.84%
1 Year
+56.85%
+56.85%

More News

Read More
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
Via MarketBeat
Exposures Product Safety
Market Whales and Their Recent Bets on ALNY Options
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
Via Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Via Benzinga
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations
Via Investor's Business Daily
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
Via Benzinga
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
The 3 Best Gene Editing Stocks to Buy in August 2024
Via InvestorPlace
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
Via Investor's Business Daily
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Via Benzinga
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Via Benzinga
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Stock Is a Blockbuster Biopharma In the Making
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.